Patrys today announced that it has received positive draft reports for two recently completed Good Laboratory Practice (GLP) toxicology studies testing PAT-DX1 in rats and a non‑human primate species.
The preliminary reports show that PAT-DX1 is safe and well-tolerated in both animal species. Two more reports that will provide additional information on the toxicity of PAT-DX1 are expected by the end of July.
Patrys CEO & MD, Dr. James Campbell said:
“We are very pleased to have completed these two toxicology studies in rats and a non‑human primates and have them confirm the favourable safety profile that we have seen for PAT‑DX1 to date. These studies are expected to complete the regulatory safety requirements that need to be fulfilled in order to start a clinical trial in cancer patients.”